N-Zyme was founded by its directors; Franco Vigile, an entrepreneur with first hand experience in dealing with LPR and Nikki Johnston, Ph.D., who dedicated her career to LPR research.
Entrepreneur with over 10 years experience in founding/operating successful companies. Founder of HaluGen, a leading genetic-based pre-screening platform, and GENNCO Holdings, a Canadian boutique advisory firm.
Nikki has 20 years experience in LPR and pepsin research, supporting the clinical trial. She is currently part of the team preparing international evidence-based guidelines for the definition and the diagnosis of LPR.
Dr. Brian Jahns is an accomplished senior executive whose extensive experience spans pharma and biotech, mature organisations, and start-ups. His expertise spans operational and commercial excellence, formulation of strategy, licensing, partnering, and scientific affairs.
We bring together industry experts from the business, science and medical communities that are working together to create revolutionary treatments for individuals suffering with reflux disorders such as Laryngopharyngeal Reflux (LPR).
With almost four decades of clinical and scientific research focused on the diagnosis, treatment, and cell biology of reflux, Dr. Koufman personally coined the terms laryngopharyngeal reflux, silent reflux, airway reflux, and the newest term, respiratory reflux.
Prakash Gowd brings over 25 years of experience in executive management, strategic business analysis, corporate development, financing, and capital markets focused on the healthcare and biopharma sectors.
Dr. Carroll's research focuses on the symptom overlap of glottic insufficiency and laryngopharyngeal reflux disease. He has a special interest in non-acidic reflux and chronic cough. His research focuses on the symptom overlap of glottic insufficiency and laryngopharyngeal reflux disease.
Jerome is a 33 yo Otolaryngologist (M.D., Ph.D., M.Sc.) from Foch Hospital (Paris) and CHU de Bruxelles (Brussels). He is Professor of Otolaryngology, Anatomy & Physiology at University of Mons, Belgium.
Dana’s industry experience includes the development of regulatory strategies throughout various phases of clinical investigation, extensive interactions with regulatory authorities, and submissions to health agencies in the United States, Canada and Europe. In addition, she has implemented and maintained quality systems, prepared for and participated in agency audits, and developed internal training programs.
Dr. Hastedt has over 35 years of experience in pharmaceutical product development, managing and leading the development of small molecules, peptides, and proteins. Supported successful US and EU regulatory approvals. Her experience includes leading physicochemical characterization and CMC development activities spanning early drug product development and launch.
Enter your email to get the latest developments on N-Zyme, including our research, clinical trials and corporate reports.